J&J enlists NYU to evaluate compassionate use requests

Johnson & Johnson (NYSE:JNJ) said New York University School of Medicine will establish the Compassionate-Use Advisory Committee (CompAC), an independent committee to help the company evaluate compassionate use requests from individuals seeking access to J&J compounds that are not yet approved. The 10-member advisory committee will consist of medical experts, bioethicists and patient representatives.

CompAC will initially evaluate compassionate use requests for a single J&J compound, which company spokesperson Larry Thompson declined to name. He said the program will likely continue through YE15 and will end when J&J launches the therapy, assuming FDA approves it. ...